Ownership and insider activity for Kalaris Therapeutics Inc (KLRS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Price
| Price | $3.18 |
| Market Cap | $69M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-27 | Vandekop Amy O'Leary | A-Award | 10,000 | $41K |
| 2026-08-01 | KEATING LAURIE | A-Award | 18,000 | $63K |
| 2026-08-01 | KEATING LAURIE | |||
| 2026-07-27 | Vandekop Amy O'Leary | |||
| 2026-07-27 | Vandekop Amy O'Leary | 27,415 | $200K | |
| 2026-07-27 | Vandekop Amy O'Leary | 20,000 | $136K | |
| 2026-07-20 | Bayko Liisa Ann | A-Award | 220,000 | $880K |
| 2026-07-20 | Bayko Liisa Ann | |||
| 2026-06-03 | Jovan-Embiricos Morana | A-Award | 9,000 | $42K |
| 2026-06-03 | Ferrara Napoleone | A-Award | 9,000 | $42K |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $25.0M | $61.1M | $122.7M | $201.7M | $3.1M | $3.2M | $118.3M | $98.1M |
| Short-term Investments | 0 | $65.0M | $233.7M | $46.5M | 0 | 0 | 0 | $19.9M |
| Receivables | $302000 | $560000 | $450000 | $50000 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $25.3M | $127.3M | $361.3M | $253.3M | $3.9M | $3.3M | $118.5M | $118.8M |
| Property, Plant & Equipment | 0 | $12.1M | $9.5M | $31.3M | 0 | 0 | 0 | $1.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $25.3M | $139.4M | $370.8M | $286.6M | $3.9M | $3.3M | $118.5M | $121.7M |
| Accounts Payable | $153000 | $630000 | $963000 | $8.4M | $2.8M | $2.4M | $247000 | $1.3M |
| Short-term Debt | 0 | $3.1M | $3.2M | $6.6M | 0 | 0 | 0 | $316000 |
| Total Current Liabilities | $3.7M | $9.1M | $12.3M | $37.9M | $5.7M | $3.9M | $5.2M | $9.7M |
| Long-term Debt | 0 | 0 | 0 | 0 | $3.3M | 0 | 0 | 0 |
| Total Liabilities | $3.7M | $17.8M | $17.8M | $61.3M | $34.2M | $48.4M | $5.2M | $42.9M |
| Retained Earnings | -$31.5M | -$55.3M | -$125.1M | -$297.1M | -$32.7M | -$47.4M | -$715.0M | -$160.0M |
| Total Equity | $21.6M | $121.6M | $353.1M | $225.3M | -$30.3M | -$45.0M | $113.3M | $78.8M |
| Total Debt | 0 | $11.8M | $8.7M | $30.1M | $3.3M | 0 | 0 | $1.4M |
| Net Debt | -$25.0M | -$114.3M | -$347.6M | -$218.1M | $194000 | -$3.2M | -$118.3M | -$116.5M |
| Working Capital | $21.6M | $118.2M | $349.0M | $215.5M | -$1.8M | -$609000 | $113.3M | $109.1M |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 10.98 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -0.21 |
Profitability
| Return on Equity | -71.71% |
| Return on Invested Capital | -52.40% |
| Return on Assets | -44.47% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ARTV · CNTB · CNTX · IFRX · IMA · MGX · OVID
Explore sector: Healthcare · Biotechnology
More sections of KLRS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks